KRAS and non-small cell lung carcinoma: To better understand the mechanism behind gemcitabine chemoresistance in KRAS mutated cells we developed H23-GR and SW1573-GR cell lines, highlighting that chronic gemcitabine exposure induces significant transcriptional and cellular adaptations in NSCLC cells, promoting the development of resistance.